Week in Review: Nearly $2B Late-December Week for China Pharma Deals

December 23, 2017

Deals and Financings

• Nanjing Legend Biotech received a very large $350 million upfront payment from Janssen Biotech to partner Legend’s impressively effective CAR-T candidate;
• Crown Bioscience, a CRO with facilities in China and elsewhere, will be acquired for $400 million by Japan’s JSR, double its previous valuation;